Less Ads, More Data, More Tools Register for FREE

Pin to quick picksNetscientific Regulatory News (NSCI)

  • There is currently no data for NSCI

Board Change

9 Nov 2022 07:00

RNS Number : 7543F
NetScientific PLC
09 November 2022
 

For release: 9 November 2022

NetScientific plc

("NetScientific" or "NSCI" or the "Company" or the "Group")

Board Change

London, UK - 9 November 2022: NetScientific Plc (AIM: NSCI), the active international holding company, which invests in, develops, and commercialises life sciences/healthcare, sustainability, and technology companies, today announces that John Clarkson is relinquishing his executive status and becoming Non-Executive Chairman of the Company with immediate effect.

John joined the NetScientific Board in December 2019, was appointed as Non-Executive Chairman in March 2020, and stepped into the role of Executive Chairman in December 2020. During this three year period, the Company has made substantial progress with the turnaround of the business and implementation of its growth strategy to deliver shareholder value, with proactive commercial management, a capital light investment model, trans-Atlantic development, and expansion of the portfolio from 8 to 23 companies.

John has indicated his wish to step down from the NetScientific Board during the first quarter of 2023 and has agreed to remain in the role of Non-Executive Chairman of the Company whilst the Company concludes its search for the appointment of a new Chair. It has also been agreed that John will, until 31 December 2023, provide various consultancy and advisory services to Group companies for an aggregate remuneration that is within his contractual entitlement to payment in lieu of notice.

The Nomination Committee has initiated a search for a new Chair and an announcement will be made in due course.

In the meantime, the Board thanks John for his commitment and support in his capacity as Executive Chairman and looks forward to continuing to work with him in his new role.

The person responsible for arranging the release of this announcement on behalf of the Company is Ilian Iliev, Chief Executive of the Company.

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF THE UK VERSION OF REGULATION (EU) NO 596/2014 WHICH IS PART OF UK LAW BY VIRTUE OF THE EUROPEAN UNION (WITHDRAWAL) ACT 2018, AS AMENDED. UPON THE PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INSIDE INFORMATION IS NOW CONSIDERED TO BE IN THE PUBLIC DOMAIN.

 

For more information, please contact:

 

NetScientific

Ilian Iliev, CEO Via Belvedere Communications

 

WH Ireland (NOMAD, Financial Adviser and Broker)

Chris Fielding / Darshan Patel / Enzo Aliaj +44 (0)20 7220 1666

 

Belvedere Communications

John West / Llew Angus +44 (0) 203 008 6867

Email: nsci@belvederepr.com

 

About NetScientific

NetScientific Plc ("NSCI") is an active holding Company that proactively invests in a global portfolio of companies across the healthcare, life science, ESG, and deep technology sectors.

NetScientific delivers shareholder returns through a proactive and hands-on management approach to its portfolio companies; identifying, investing in, and helping to build game-changing companies. The Group targets value inflection points and the release of value through partial or full exits from trade sales, public listings, or equity sales. The Company has a strong Trans-Atlantic and growing international presence, providing attractive expansion prospects.

The Company differentiates itself by employing a capital-light investment approach, making use of its wholly owned subsidiary, EMV Capital's network of private, corporate, and institutional investors. By syndicating investment and making minimal use of its balance sheet, the Company is able to secure direct stakes, as well as carried interest stakes, in its portfolio. This ultimately creates a structure that can support a large portfolio with a limited balance sheet.

NetScientific is headquartered in London, United Kingdom, and was admitted to trading on AIM, a market operated by the London Stock Exchange, in 2013.

www.netscientific.net

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
BOABPBTTMTBMTLT
Date   Source Headline
6th Jan 20167:00 amRNSGlycotest Inc. appoints medical advisory board
4th Jan 20167:00 amRNSWANDA signs contract with HRS
16th Dec 20157:00 amRNSLawrence Cohen appointed as CEO of Glycotest Inc.
14th Dec 20157:00 amRNSAppointment of Gene Walther as Vortex CEO
3rd Dec 20157:00 amRNSProAxsis' ProteaseTagT research update
30th Nov 20157:00 amRNSProAxsis presents data to validate its immunoassay
16th Nov 20157:00 amRNSIssue of Equity
11th Nov 20157:00 amRNSHolding(s) in Company
10th Nov 20157:00 amRNSGrant of Options
6th Nov 201512:14 pmRNSResult of General Meeting
3rd Nov 20154:29 pmRNSHolding(s) in Company
21st Oct 20151:52 pmRNSPosting of Circular
1st Oct 20157:00 amRNSProposed Placing and Fund Raising to raise c.£20m
1st Oct 20157:00 amRNSHalf Yearly Report
18th Sep 20157:00 amRNSDivestment of Shareholding in Frontier BioSciences
16th Sep 20151:01 pmRNSHolding(s) in Company
15th Sep 20157:00 amRNSVortex BioSciences granted critical patent
9th Sep 20151:00 pmRNSSteve Curd appointed as CEO of Wanda
7th Aug 20157:00 amRNSDivestment of non-core assets to align portfolio
4th Aug 20157:00 amRNSProAxsis launches first-in-class ProteaseTag test
15th Jul 20157:00 amRNSKey patent granted for Glucosense's technology
22nd Jun 20151:19 pmRNSResults of Annual General Meeting
22nd Jun 20157:00 amRNSAGM Statement
5th Jun 20155:46 pmRNSNotification of Major Interest in Shares
5th Jun 20155:42 pmRNSNotification of Major Interest in Shares
5th Jun 20155:38 pmRNSNotification of Major Interest in Shares
5th Jun 20152:00 pmRNSNotification of Major Interest in Shares
5th Jun 20152:00 pmRNSNotification of Major Interest in Shares
28th May 201512:02 pmRNSPDS Biotechnology reports positive Phase I results
18th May 20157:00 amRNSNotice of AGM and Annual Report & Accounts
15th May 20157:00 amRNSCapital Markets Day
11th May 20157:00 amRNSDr. François R. Martelet appointed as CEO
7th May 20157:00 amRNSNetScientific invests in Neumitra
1st May 20157:00 amRNSNetScientific Forms New Digital Health Company
29th Apr 20159:00 amRNSNetScientific Capital Markets Day
1st Apr 20157:00 amRNSChange of Adviser
24th Mar 20157:00 amRNSSignificant Progress in core Portfolio Companies
20th Mar 20152:00 pmRNSNotice of Full Year Results
26th Feb 201510:07 amRNSAppointment of Non-Executive Director
16th Jan 20156:19 pmRNSDirectorate Change
7th Jan 20151:04 pmRNSNetScientific teams up with KU Leuven
7th Jan 20151:04 pmRNSNetScientific invests in DName-iT
15th Dec 20147:00 amRNSNetScientific invests in PDS Biotechnology
11th Dec 20147:00 amRNSNetScientific enters into alliance with Healthbox
8th Dec 20147:00 amRNSNetScientific invests in Breakout Labs' portfolio
17th Nov 20143:36 pmRNSHolding(s) in Company
17th Nov 20141:26 pmRNSHolding(s) in Company
3rd Oct 20147:00 amRNSSubsidiary, Glycotest collaboration with Oncimmune
23rd Sep 20147:00 amRNSHalf Yearly Report
17th Sep 20142:00 pmRNSNotice of Half Yearly Report

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.